DSIP Peptide: What the Sleep Research Actually Shows

In 1974 a Swiss group led by Schoenenberger and Monnier took blood from the cerebral veins of rabbits whose brains were being stimulated into slow-wave sleep, and found that something in the dialysate would induce delta-wave EEG activity when given to another animal. Four years later they published the sequence. That nonapeptide is what the research literature calls DSIP.

Where the DSIP peptide came from

The isolation experiment is unusual enough to be worth stating plainly. Monnier’s group ran electrical stimulation of the thalamus in donor rabbits to drive them into delta sleep, dialysed the blood leaving the brain, and transferred the dialysate to recipient animals. The recipients showed increased delta EEG activity. Whatever was in that fraction was named for the effect, not for a mechanism, because no mechanism was known.

The 1978 paper in Pflügers Archiv reported the amino-acid analysis, the sequence, a synthesis, and a blinded test of the synthetic material against variants in 61 rabbits. Only the pure alpha-aspartyl form was active, producing roughly a 35% rise in delta activity across cortical leads. That detail matters: a positional isomer of a single residue abolished the effect.

The sequence, and what it does not tell you

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu is about 850 daltons. Read it as a chemist and three things stand out. It is small. It is unusually flexible — three glycines in nine residues means very little conformational constraint. And it is acidic, carrying aspartate and glutamate with no basic residues to balance them, which is why it dissolves readily in water at neutral pH.

What the sequence does not tell you is what it binds. A short, flexible, acidic peptide with no obvious recognition motif is exactly the kind of molecule that resists structure-based reasoning about its target.

No receptor has ever been identified

This is the central fact of the field and it is routinely glossed over. There is no cloned DSIP receptor. There is no confirmed precursor protein and no identified gene, including in the rabbit the peptide was isolated from. Proposals in the literature have pointed at NMDA and at alpha-1 adrenergic signalling, but these are proposals rather than established pharmacology.

A compound without a known receptor is not automatically inert. It does mean that dose-response reasoning, selectivity claims and comparisons with other sleep-active compounds have no molecular anchor. Anyone who tells you how it works is going beyond the published record.

A fifteen-minute half-life

In vitro, DSIP has been measured with a half-life of roughly fifteen minutes, degraded by a specific aminopeptidase-like activity. That is short even by peptide standards, and it is the reason synthetic analogues exist at all: several modified forms show stronger and longer activity in animal models than the natural sequence does.

Short half-life also shapes how the material behaves in a vial. A peptide this labile to aminopeptidase in plasma is not necessarily unstable as a lyophilised powder — the two are different questions — but it does mean anything left in solution at room temperature is a different sample an hour later.

What the DSIP peptide sleep evidence actually shows

Honestly: it is mixed, and it has been mixed for decades. Some studies report promotion of slow-wave sleep and suppression of REM. Others find no correlation at all. Human work has been small, heterogeneous in design, and largely historical. No regulator anywhere has approved it for anything.

The useful way to hold this is as an interesting unresolved question rather than a settled tool. A compound named for an effect, isolated by an effect, and still without a receptor half a century later is a research subject, not a conclusion.

• Isolated 1974; sequenced and synthesised 1978
• Nine residues, roughly 850 Da
• No receptor, gene or precursor confirmed
• About fifteen minutes in-vitro half-life
• Sleep findings inconsistent across studies

Handling and storing the DSIP peptide

Nothing here changes the standard handling rules for a lyophilised research peptide. Keep the sealed vial cold and dark. Reconstitute slowly down the vial wall rather than directly onto the powder cake. Do not shake. Once in solution, keep it refrigerated and treat time at room temperature as a cost.

Because the sequence is acidic and free of hydrophobic runs, it goes into bacteriostatic water without argument — no organic co-solvent, no pH adjustment. If a vial refuses to clear, the answer is almost always aggregation or an undissolved cake rather than a solubility limit.

Frequently asked questions

References

The primary literature below is indexed on PubMed, and compound records are held at PubChem.

• Schoenenberger GA, Maier PF, Tobler HJ, Wilson K, Monnier M. The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflügers Archiv 1978. PubMed 568769
• Monnier M, Schoenenberger GA and colleagues, the delta EEG (sleep)-inducing peptide series, Pflügers Archiv, from 1974 onward.

All Soraci Labs products are sold for laboratory research use only. They are not drugs, supplements or cosmetics, and are not for human or veterinary use, diagnosis or treatment. Nothing on this page is guidance for use in people.